Here are some of the latest health and medical news
developments, compiled by the editors of HealthDay:
Company Recalls Frozen Berry Mix Linked to Hepatitis
A frozen berry mix linked to an outbreak of hepatitis A that has
affected at least 34 people in five states has been recalled by
Townsend Farms of Oregon, the U.S. Food and Drug Administration
The recall involves the company's frozen Organic Antioxidant
Blend, which is packaged under the Townsend Farms label at Costco
and under the Harris Teeter brand at those stores, the
The recall came three days after federal officials first
announced a suspected link between the frozen berry mix and the
illnesses in Arizona, California, Colorado, New Mexico and Nevada.
The FDA, which is inspecting Townsend Farms' processing facilities,
did not explain why there was not an immediate recall.
The outbreak involves a strain of hepatitis A rarely seen in
North or South America, but which is found in North Africa and the
Middle East, according to the Centers for Disease Control and
Last week, a lawyer for Townsend Farms said the frozen berry
product associated with the outbreak includes pomegranate seeds
from Turkey, the
No Misconduct or Fraud in Avandia Study: FDA
A review found no serious misconduct or fraud in a controversial
clinical trial that minimized safety issues involving the diabetes
drug Avandia, according to U.S. Food and Drug Administration
The FDA team said they supported the findings of the review by
Duke University researchers, who determined that any errors made by
drug maker GlaxoSmithKline had no effect on the conclusions of the
company's clinical trial of Avandia,
The New York Timesreported.
The FDA experts' opinion was posted Monday on the FDA website,
along with a critical memo by FDA scientist Dr. Thomas Marciniak,
who originally raised concerns about the Glaxo study. Marciniak
questioned whether the review by the Duke researchers was truly
objective because it was financed by Glaxo.
In 2010, the FDA imposed tight restrictions on the use of
Avandia after several analyses showed that the drug significantly
increased the risk of heart attack. The drug was removed from the
market in Europe.
The conflicting viewpoints were posted on the FDA website in
advance of a two-day meeting of an FDA advisory panel scheduled to
begin Wednesday. The panel will discuss the issue and recommend to
the FDA whether to widen access to Avandia, keep the current
restrictions in place, or take the drug off the market,
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.